Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Select Medical Holdings (SEM) Asset Writedowns and Impairment (2018 - 2025)

Select Medical Holdings (SEM) has disclosed Asset Writedowns and Impairment for 7 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment rose 135.47% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.4 million, a 44.8% decrease, with the full-year FY2025 number at $2.4 million, down 44.8% from a year prior.
  • Asset Writedowns and Impairment was $2.4 million for Q4 2025 at Select Medical Holdings, up from -$1.6 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $9.5 million in Q3 2024 to a low of -$6.7 million in Q4 2024.
  • A 5-year average of $403736.8 and a median of $94000.0 in 2022 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: soared 1852.94% in 2023, then tumbled 878.95% in 2024.
  • Select Medical Holdings' Asset Writedowns and Impairment stood at -$172000.0 in 2021, then soared by 35.47% to -$111000.0 in 2022, then soared by 870.27% to $855000.0 in 2023, then crashed by 878.95% to -$6.7 million in 2024, then skyrocketed by 135.47% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for SEM's Asset Writedowns and Impairment are $2.4 million (Q4 2025), -$1.6 million (Q3 2025), and -$728000.0 (Q2 2025).